This is a StreetInsider.com Premium Only Page

(VIRI) – Globe Newswire

Mar 26, 2024 09:15 AM Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Feb 29, 2024 09:15 AM Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024 09:15 AM Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Jan 22, 2024 09:00 AM Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 2, 2024 07:05 AM Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Nov 13, 2023 07:05 AM Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023 07:05 AM Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Oct 12, 2023 07:05 AM Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Sep 18, 2023 07:05 AM Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 12, 2023 07:05 AM Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Aug 14, 2023 07:05 AM Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 10, 2023 07:05 AM Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 9, 2023 07:05 AM Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Aug 3, 2023 04:05 PM Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 17, 2023 07:05 AM Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Labe

May 25, 2023 04:05 PM Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023 07:05 AM Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 11, 2023 07:05 AM Virios Therapeutics Announces First Quarter 2023 Financial Results

May 4, 2023 07:05 AM Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Apr 24, 2023 04:15 PM Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Mar 14, 2023 07:05 AM Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 7, 2023 07:05 AM Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

Feb 13, 2023 07:05 AM Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Jan 5, 2023 07:00 AM Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

Sep 16, 2022 09:30 AM New to The Street TV / Newsmax TV Announces its Eight Interviews on This Week's TV Broadcast, Episode #386, September 18, 2022, 10-11 AM ET

Sep 12, 2022 09:30 AM New to The Street TV Announces Four Corporate Interviews on its 384th TV Show, Airing on the Fox Business Network, Tonight, Monday, September 12, 2022, at 10:30 PM PT